Vol 9, Supplement 1 (February 28, 2020): Translational Lung Cancer Research (Mesothelioma: What We know and What We Do Not Know in 2020)

Review Article

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma
David B. Chapel, Jefree J. Schulte, Aliya N. Husain, Thomas Krausz
Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use
Naomi Alpert, Maaike van Gerwen, Emanuela Taioli
How asbestos and other fibers cause mesothelioma
Giovanni Gaudino, Jiaming Xue, Haining Yang
SV40 and human mesothelioma
Michele Carbone, Adi Gazdar, Janet S. Butel
BAP1: role in carcinogenesis and clinical implications
Daniel A. Kobrinski, Haining Yang, Muaiad Kittaneh
Mesothelioma developing in carriers of inherited genetic mutations
Yoshie Yoshikawa, Mitsuru Emi, Takashi Nakano, Giovanni Gaudino
Chemotherapy options versus “novel” therapies: how should we treat patients with malignant pleural mesothelioma
Maria J. Disselhorst, Paul Baas
Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
Gavitt A. Woodard, David M. Jablons
Chromosomal rearrangements and their neoantigenic potential in mesothelioma
Aaron Scott Mansfield, Tobias Peikert, George Vasmatzis
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
Steven G. Gray, Luciano Mutti
Peritoneal mesothelioma
Alissa Greenbaum, H. Richard Alexander


The supplement “Mesothelioma: What We know and What We Do Not Know in 2020” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Michele Carbone served as the unpaid Guest Editor for the supplement.